RemedyOne

RemedyOne cuts through the complexity of modern pharmaceutical programs to uncover opportunities to grow, to flex agreements in your favor and to help you take decisive action on what matters.

Webinar On-Demand: Breaking Down the Hottest Topic in Pharmacy: Humira Biosimilars

Uncover what could happen with Humira and the biosimilar market in 2023  While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market. Will biosimilar competitors increase competition, lower drug costs and knock Humira …

Webinar On-Demand: Breaking Down the Hottest Topic in Pharmacy: Humira Biosimilars Read More »

Potent Veterinary Drug Resistant to Narcan and It’s Rising Illicit Use Among Humans – RemedyOne’s Rob Louie Quoted in an Insightful Analysis with Fox News

A Fox News article recently quoted RemedyOne EVP of clinical services Rob Louie on xylazine, a potent veterinary drug that has seen a recent uptick in illicit human use. Rob helped add context to an alert from the U.S. Drug Enforcement Administration on xylazine. Below is the complete interview, which Rob prepared for in collaboration …

Potent Veterinary Drug Resistant to Narcan and It’s Rising Illicit Use Among Humans – RemedyOne’s Rob Louie Quoted in an Insightful Analysis with Fox News Read More »

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars

The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be a test for industry stakeholders, as their entrance will reveal whether blockbuster drugs—that offer significant rebates—can be replaced to reduce the cost burden on patients and payers in the United States. Download our …

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars Read More »

Uncovering Solutions for Affordable Drug Pricing

The House Committee on Oversight and Reform held a series of hearings to review findings from an in-depth investigation into drug pricing actions that was conducted last year with CEOs representing some of the largest and most profitable pharmaceutical manufacturers. As stated in the summary report of the investigation by Chairwoman Carolyn Maloney, “the drug …

Uncovering Solutions for Affordable Drug Pricing Read More »